



Bölüm 14

Küçük Hücreli Akciğer Kanseri

Mert SAYNAK¹ Seda DEMİR²



Giriş

Küçük hücreli akciğer kanseri (KHAK), akciğer kanserlerinin ~ %15'ini oluşturur^{1,2}. İlk olarak 1960'lı yıllarda ayrı bir patolojik tip olarak tanımlanmıştır³. Tedavisinde uzun süre değişiklik olmaması nedeniyle "unutulmuş hastalık/öksüz hastalık" olarak nitelenmiştir. Sisplatin-etoposid kombinasyonu ile %80-85 cevap ve %25 tam cevap elde edilebilmektedir⁴. Bu iyi cevap oranlarını ve progresyonsuz süreyi aşan ilaç kombinasyonu son döneme kadar belirlenmemiştir. Son dönemde metastatik hastalıkta immün tedaviler devreye girmiştir ve bu konudaki çalışmalar hızla ilerlemektedir^{5,6}.

Epidemiyoloji, Risk Faktörleri ve Prognosa Etki Eden Faktörler:

KHAK'nin hızla yayılma eğilimi vardır ve hastaların ~2/3'si metastatik hastalıkla başvurur⁴. Genellikle tanıdan birkaç hafta önce kısa bir semptom öyküsü vardır. Sigara kullanımı KHAK gelişimi için en önemli risk faktörüdür. Sigara kullanımındaki azalmaya bağlı olarak insidansında azalma olduğu bildirilmiştir¹. Tütün

ürünleri kullanımının bırakılması hastaya önerilir. Sigaraya devam eden hastaların sağkalım süreleri kısalmaktadır. Bunun yanında, sigara içmeye devam eden hastalarda ikinci primer tümörler daha sık görülmektedir^{7,8}.

Kötü performans durumu, yaygın hastalık, kilo kaybı (6 ay içinde >% 5), yüksek LDH değeri, erkek cinsiyet, endokrin paraneoplastik sendromlar (tartışmalı), varyant veya mikst hücre tipi olumsuz prognostik faktörleri oluşturmaktadır⁹.

Genellikle santral yerleşimli tümörler olduğundan öksürük, nefes darlığı gibi bası bulguları ile ilişkilidir. Yaygın hastalıkta kilo kaybı ya da metastatik bölgeye özgü belirti ve bulgular olabilir. Paraneoplastik olayların prevalansı yüksektir. Hastaların ~%15'inde uygunsuz antidiüretik hormon sekresyonu ve buna bağlı hiponatremi gelişir. Cushing Sendromu, hastaların %5'inde ortaya çıkar ve bu hastalarda obezite, hirsutizm, glukoz intoleransı ve akne gelişimi olabilir. Lambert-Eaton Sendromu, kalsiyum kanallarını hedefleyen antikora bağlıdır ve proksimal kas zayıflığı ile karakterizedir¹⁰.

Tedavisiz oldukça hızlı bir seyir gösterir ve

¹ Prof. Dr. Mert SAYNAK, Trakya Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Bölümü mertsaynak@yahoo.com

² Dr. Öğr. Üyesi Seda DEMİR Trakya Üniversitesi Tıp Fakültesi Radyasyon Onkolojisi Bölümü sedacyhnnn@gmail.com

Kaynaklar

1. Daly ME, Ismaila N, Decker RH, Higgins K, Owen D, Saxena A, et al. Radiation therapy for small-cell lung cancer: Asco guideline endorsement of an astro guideline. *J Clin Oncol*. 2021;39:931-939
2. Simone CB, 2nd, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, et al. Radiation therapy for small cell lung cancer: An astro clinical practice guideline. *Pract Radiat Oncol*. 2020;10:158-173
3. Watson WL, Berg JW. Oat cell lung cancer. *Cancer*. 1962;15:759-768
4. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: Have we made any progress over the last 25 years? *Oncologist*. 2007;12:1096-1104
5. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med*. 2018;379:2220-2229
6. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (caspien): A randomised, controlled, open-label, phase 3 trial. *Lancet*. 2019;394:1929-1939
7. Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. *J Clin Oncol*. 2003;21:1544-1549
8. Kawahara M, Ushijima S, Kamimori T, Kodama N, Ogawara M, Matsui K, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in japan: The role of smoking cessation. *Br J Cancer*. 1998;78:409-412
9. Glatzer M, Rittmeyer A, Muller J, Opitz I, Papachristofilou A, Psallidas I, et al. Treatment of limited disease small cell lung cancer: The multidisciplinary team. *Eur Respir J*. 2017;50
10. Jackman DM, Johnson BE. Small-cell lung cancer. *Lancet*. 2005;366:1385-1396
11. Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, Agra Varela Y. Chemotherapy versus best supportive care for extensive small cell lung cancer. *Cochrane Database Syst Rev*. 2009:CD001990
12. Vallieres E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. The iaslc lung cancer staging project: Proposals regarding the relevance of tnm in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the tnm classification for lung cancer. *J Thorac Oncol*. 2009;4:1049-1059
13. Zelen M. Keynote address on biostatistics and data retrieval. *Cancer Chemother Rep*. 1973;4:31-42
14. Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Groome P, et al. The iaslc lung cancer staging project: External validation of the revision of the tnm stage groupings in the eighth edition of the tnm classification of lung cancer. *J Thorac Oncol*. 2017;12:1109-1121
15. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. *Chest*. 1994;106:320S-323S
16. Yang CF, Chan DY, Speicher PJ, Gulack BC, Wang X, Hartwig MG, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. *J Clin Oncol*. 2016;34:1057-1064
17. Schreiber D, Rineer J, Weedon J, Vongtama D, Wortham A, Kim A, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: Should its role be re-evaluated? *Cancer*. 2010;116:1350-1357
18. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A japanese lung cancer registry study: Prognosis of 13,010 resected lung cancers. *J Thorac Oncol*. 2008;3:46-52
19. Chen H, Laba JM, Zayed S, Boldt RG, Palma DA, Louie AV. Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: A systematic review. *J Thorac Oncol*. 2019;14:1332-1342
20. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase iii trial of the southeastern cancer study group. *J Clin Oncol*. 1992;10:282-291
21. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. *J Clin Oncol*.

- 1994;12:2022-2034
22. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, et al. Randomised phase iii trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: Jcoog 9702. *Br J Cancer*. 2007;97:162-169
 23. Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy. *J Natl Cancer Inst*. 1997;89:577-580
 24. Fruh M, De Ruyscher D, Popat S, Crino L, Peters S, Felip E, et al. Small-cell lung cancer (sclc): Esmo clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013;24 Suppl 6:vi99-105
 25. de Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, et al. Phase iii study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. *Eur J Cancer*. 2007;43:2345-2350
 26. Faivre-Finn C, Lee LW, Lorigan P, West C, Thatcher N. Thoracic radiotherapy for limited-stage small-cell lung cancer: Controversies and future developments. *Clin Oncol (R Coll Radiol)*. 2005;17:591-598
 27. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase iii study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the japan clinical oncology group study 9104. *J Clin Oncol*. 2002;20:3054-3060
 28. Turrisi AT, 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med*. 1999;340:265-271
 29. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. *J Clin Oncol*. 1997;15:893-900
 30. Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase iii trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. *Ann Oncol*. 2013;24:2088-2092
 31. De Ruyscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. *J Clin Oncol*. 2006;24:1057-1063
 32. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (convert): An open-label, phase 3, randomised, superiority trial. *Lancet Oncol*. 2017;18:1116-1125
 33. Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: An open-label, randomised, phase 2 trial. *Lancet Oncol*. 2021;22:321-331
 34. Bogart JA, Herndon JE, 2nd, Lyss AP, Watson D, Miller AA, Lee ME, et al. 70 gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: Analysis of cancer and leukemia group b study 39808. *Int J Radiat Oncol Biol Phys*. 2004;59:460-468
 35. Bogart J, Wang X, Masters G, Zhu H, Komaki R, Gaspar L, et al. Interim toxicity analysis for patients with limited stage small cell lung cancer (lsccl) treated on the experimental thoracic radiotherapy (trt) arms of calgb 30610 (alliance)/rtog 0538. *Annals of Oncology*. 2019;30:v711
 36. Fowler JF. 21 years of biologically effective dose. *Br J Radiol*. 2010;83:554-568
 37. Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, et al. Phase iii comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. *J Clin Oncol*. 1999;17:2681-2691
 38. Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, et al. Long-term results of a phase iii trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2004;59:943-951
 39. Gronberg BH, Halvorsen TO, Flotten O, Brustugun OT, Brunsvig PF, Aasebo U, et al. Randomized phase ii trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. *Acta Oncol*. 2016;55:591-597
 40. De Ruyscher D, Bremer RH, Koppe F, Wanders S, van Haren E, Hochstenbag M, et al. Omission of elective node irradiation on basis of ct-scans in pa-

- tients with limited disease small cell lung cancer: A phase ii trial. *Radiother Oncol.* 2006;80:307-312
41. van Loon J, De Ruyscher D, Wanders R, Boersma L, Simons J, Oellers M, et al. Selective nodal irradiation on basis of (18)fdg-pet scans in limited-disease small-cell lung cancer: A prospective study. *Int J Radiat Oncol Biol Phys.* 2010;77:329-336
 42. Hu X, Bao Y, Xu YJ, Zhu HN, Liu JS, Zhang L, et al. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. *Cancer.* 2020;126:840-849
 43. Le Pechoux C, Faivre-Finn C, Ramella S, McDonald F, Manapov F, Putora PM, et al. Estro acrop guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. *Radiother Oncol.* 2020;152:89-95
 44. De Ruyscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Pechoux C, et al. European organization for research and treatment of cancer (eortc) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. *Radiother Oncol.* 2017;124:1-10
 45. Boda-Heggemann J, Knopf AC, Simeonova-Chergou A, Wertz H, Stieler F, Jahnke A, et al. Deep inspiration breath hold-based radiation therapy: A clinical review. *Int J Radiat Oncol Biol Phys.* 2016;94:478-492
 46. Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. *J Clin Oncol.* 1999;17:2092-2099
 47. Slotman BJ, van Tinteren H, Praag JO, Kneijens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: A phase 3 randomised controlled trial. *Lancet.* 2015;385:36-42
 48. Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized phase ii study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ed sclc): Nrg oncology rtog 0937. *J Thorac Oncol.* 2017;12:1561-1570
 49. Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, et al. Prospective single-arm phase 1 and 2 study: Ipilimumab and nivolumab with thoracic radiation therapy after platinum chemotherapy in extensive-stage small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2021;109:425-435
 50. Formenti SC. Optimizing dose per fraction: A new chapter in the story of the abscopal effect? *Int J Radiat Oncol Biol Phys.* 2017;99:677-679
 51. Takahashi T, Yamanaka T, Seto T, Harada H, Nohara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: A multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2017;18:663-671
 52. Arriagada R, Le Chevalier T, Riviere A, Chomy P, Monnet I, Bardet E, et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: Analysis of 505 randomized patients. *Ann Oncol.* 2002;13:748-754
 53. Levy A, Le Pechoux C, Mistry H, Martel-Lafay I, Bezjak A, Lerouge D, et al. Prophylactic cranial irradiation for limited-stage small-cell lung cancer patients: Secondary findings from the prospective randomized phase 3 convert trial. *J Thorac Oncol.* 2019;14:294-297
 54. O'Kane GM, Labbe C, Doherty MK, Young K, Albaba H, Leighl NB. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. *Oncologist.* 2017;22:70-80
 55. Remon J, Besse B. Brain metastases in oncogene-addicted non-small cell lung cancer patients: Incidence and treatment. *Front Oncol.* 2018;8:88
 56. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. *N Engl J Med.* 1999;341:476-484
 57. Yang Y, Zhang D, Zhou X, Bao W, Ji Y, Sheng L, et al. Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis. *J Cancer.* 2018;9:433-439
 58. Le Pechoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (pci) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (pci 99-01, eortc 22003-08004, rtog 0212, and ifct 99-01): A randomised clinical trial. *Lancet Oncol.* 2009;10:467-474
 59. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med.*

- 2007;357:664-672
60. Hellstrom NA, Bjork-Eriksson T, Blomgren K, Kuhn HG. Differential recovery of neural stem cells in the subventricular zone and dentate gyrus after ionizing radiation. *Stem Cells*. 2009;27:634-641
 61. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (rtog 0933): A phase ii multi-institutional trial. *J Clin Oncol*. 2014;32:3810-3816
 62. Belderbos JSA, De Ruyscher DKM, De Jaeger K, Koppe F, Lambrecht MLF, Lievens YN, et al. Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in sclc (nct01780675). *J Thorac Oncol*. 2021
 63. De Dios NR, Murcia M, Counago F, Lopez J, Oses MR, Ots PS, et al. Phase iii trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2019;105:S35-S36
 64. Gondi V, Pugh SL, Mehta MP, Tome W, Benzinger T, Bovi JA, et al. Nrg oncology cc003: A randomized phase ii/iii trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer. *Journal of Clinical Oncology*. 2019;37:TPS8578-TPS8578
 65. Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, et al. Hippocampal-sparing whole-brain radiotherapy: A "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys*. 2010;78:1244-1252
 66. Counago F, de la Pinta C, Gonzalo S, Fernandez C, Almendros P, Calvo P, et al. Goecp/seor radiotherapy guidelines for small-cell lung cancer. *World J Clin Oncol*. 2021;12:115-143
 67. Wu C, Li F, Jiao SC. Prognostic factors for survival of patients with extensive stage small cell lung cancer--a retrospective single institution analysis. *Asian Pac J Cancer Prev*. 2012;13:4959-4962
 68. Tas F, Aydiner A, Topuz E, Camlica H, Saip P, Eralp Y. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. *Acta Oncol*. 1999;38:1011-1015
 69. Bydder S, Spry NA, Christie DR, Roos D, Burmeister BH, Krawitz H, et al. A prospective trial of short-fractionation radiotherapy for the palliation of liver metastases. *Australas Radiol*. 2003;47:284-288
 70. Lokich J, Kinsella T, Perri J, Malcolm A, Clouse M. Concomitant hepatic radiation and intraarterial fluorinated pyrimidine therapy: Correlation of liver scan, liver function tests, and plasma cea with tumor response. *Cancer*. 1981;48:2569-2574
 71. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. *Neuro Oncol*. 2013;15:1429-1437
 72. Sun H, Xu L, Wang Y, Zhao J, Xu K, Qi J, et al. Additional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer. *Radiat Oncol*. 2018;13:250
 73. Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, et al. Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: The fire-sclc cohort study. *JAMA Oncol*. 2020;6:1028-1037
 74. Basch E, Snyder C. Overcoming barriers to integrating patient-reported outcomes in clinical practice and electronic health records. *Ann Oncol*. 2017;28:2332-2333